Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Colorcon
AstraZeneca
Boehringer Ingelheim

Last Updated: December 4, 2022

Desipramine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for desipramine hydrochloride and what is the scope of patent protection?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Alembic Pharms Ltd, Amneal Pharms Co, Ani Pharms, Heritage Pharms, Novast Labs, Sandoz, Usl Pharma, and Validus Pharms, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for desipramine hydrochloride. Ten suppliers are listed for this compound.

Summary for desipramine hydrochloride
Recent Clinical Trials for desipramine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 4
Stanford UniversityPhase 4
State University of New York at BuffaloPhase 4

See all desipramine hydrochloride clinical trials

Pharmacology for desipramine hydrochloride
Medical Subject Heading (MeSH) Categories for desipramine hydrochloride

US Patents and Regulatory Information for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Usl Pharma DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 071867-001 Sep 9, 1987 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Ani Pharms DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 205153-003 Oct 28, 2016 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Heritage Pharms DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 207433-003 May 5, 2016 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Alembic Pharms Ltd DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 209785-003 Jul 7, 2021 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Alembic Pharms Ltd DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 209785-005 Jul 7, 2021 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Actavis Totowa DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 074430-002 Feb 9, 1996 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Mallinckrodt
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.